Skip to main content

An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.

O'Grady A, Allen D, Happerfield L, Johnson N, Provenzano E, Pinder SE, Tee L, Gu M, Kay EW

Publication: Appl Immunohistochem Mol Morphol (2010) • Vol 18 • Page 489-93PMID: 20661132View on PubMed

Purpose

The purpose of this paper was to compare results of HER2 immunostaining of formalin-fixed paraffin-embedded (FFPE) breast cancer tissue using the Dako HercepTest and the Oracle HER2 Bond Immunohistochemical System.

Conclusion

Out of the original HercepTest positive and equivocal cases, 80.6% were identified as positive or equivocal by both the Oracle and HercepTest. 98.0% of the original negative cases were scored as negative by both the Oracle and HercerpTest. The overall concordance rate between the Oracle and HercepTest methods was 86.7%. A majority of discordant cases were scored as equivocal with the HercepTest and negative with Oracle immunohistochemistry (IHC). In the majority of these cases (31/36), the HER2 gene was not amplified when analyzed by FISH.

Studies (1)

Purpose

The purpose of this study was to compare results of HER2 immunostaining of FFPE breast cancer tissue using the Dako HercepTest and the Oracle HER2 Bond Immunohistochemical System. This study included a total of 445 archival FFPE breast cancer samples collected at 3 different centers. Specimens were obtained by needle core biopsy or resection, but no further details of specimen procurement or processing were provided. Sequential sections were stained using HercepTest and the Oracle on the Bond fully automated, advanced staining system. Staining was scored by blinded pathologists as each of the three sites as negative (0,1+), equivocal (2+), and positive (3+) according to the modified ASCO/CAP and UK HER2 IHC scoring guidelines. Forty-one specimens with discordant results were further evaluated using the PathVysion HER2 FISH staining system.

Summary of Findings

Out of the original HercepTest positive and equivocal cases, 80.6% were identified as positive or equivocal by both the Oracle and HercepTest. 98.0% of the original negative cases were scored as negative by both the Oracle and HercerpTest. The overall concordance rate between the Oracle and HercepTest methods was 86.7%. A majority of discordant cases were scored as equivocal with the HercepTest and negative with Oracle IHC. In the majority of these cases (31/36), the HER2 gene was not amplified when analyzed by FISH. Use of modified ASCO/CAP and UK HER2 IHC scoring guidelines versus commercially validated HER2 IHC guidelines did not significantly influence concordance rates.

  • Biospecimens

    TissueBreast
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
    DNAFISH
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Immunohistochemistry SpecificTargeted peptide/protein
    HER2
    Immunohistochemistry SpecificTechnology platform
    Dako HercepTest
    FISH
    Oracle HER2 Bond IHC System